As FES-PET enters clinical practice, it is important to explore its utility in the full spectrum of patients with hormone (estrogen and/or progesterone) receptor positive breast cancer, including those with human epidermal growth factor 2 (HER2)-overexpressing tumors. Here, ERBB2 is linked to breast cancer.